Evidence map›Paper›PMID 41036464›Full record

ArticleMolecular therapy. Nucleic acids2025

Exploring exon excision as a therapeutic intervention strategy for the future treatment of

Merel Stemerdink, Lucija Malinar, Sanne Broekman, Theo Peters, Iris Ensink, Maryna V Ivanchenko, Hanka Venselaar, Hannie Kremer, Erik de Vrieze, Erwin van Wijk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Merel StemerdinkDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Lucija MalinarCenter for Molecular and Biomolecular Informatics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Sanne BroekmanDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Theo PetersDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Iris EnsinkDepartment of Human Genetics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Maryna V IvanchenkoDepartment of Neurobiology, Harvard Medical School, Boston, MA, USA.
Hanka VenselaarCenter for Molecular and Biomolecular Informatics, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Hannie KremerDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Erik de VriezeDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.
Erwin van WijkDepartment of Otorhinolaryngology, Radboud University Medical Center, 6525 GA Nijmegen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the lack of treatment options for

Indexed as

ADGRV1CRISPR-Cas9MT: RNA/DNA Editingmulti-exon excisionretinitis pigmentosatherapies and applicationsUsher syndrome type 2czebrafish

Identifiers

PMID41036464
PMCPMC12481715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.